Response Genetics has achieved its third milestone in its collaboration with GlaxoSmithKline related to the issuance of a U.S. patent for detection of BRAF Mutations, triggering a payment of $500,000 to Response Genetics.
The companies entered a non-exclusive license agreement in March 2010, under which GSK gained a non-exclusive license to Response Genetics PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples, in support of the development of GSK’s Tafinlar (dabrafenib). Response Genetics earned its first and second milestone payments totaling $1 million for the submission and subsequent Premarket Approval.
"We are extremely pleased to have achieved this milestone," said Thomas A. Bologna, chairman and chief executive officer of Response Genetics. "The BRAF patent approval is yet another example of the long-standing and mutually-beneficial relationship between Response Genetics and GSK. All of us at Response Genetics take pride in the role we played in the success of this important cancer therapy."